Person:
İZZETTİN, FIKRET VEHBI

Loading...
Profile Picture
Status
Organizational Units
Job Title
First Name
FIKRET VEHBI
Last Name
İZZETTİN
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 45
  • PublicationMetadata only
    Determination of CYP2C19 polymorphisms, adverse drug reaction, and medication adherence in patients utilized selective serotonin reuptake inhibitors
    (2015-02-01T00:00:00Z) Deniz, Semanur; SANCAR, MESUT; OKUYAN, BETÜL; ATA, PINAR; Bingol-Ozakpinar, Ozlem; TALAS, Anil; GUNES, Tufan; CALISKAN, Mecit; Izzettin, Fikret Vehbi; İZZETTİN, FIKRET VEHBI
  • PublicationMetadata only
    Protective effect of ferulic acid on cisplatin induced nephrotoxicity in rats
    (2017-09-01T00:00:00Z) Bami, Erliasa; Ozakpinar, Ozlem Bingol; Ozdemir-Kumral, Zarife Nigar; Koroglu, Kutay; ERCAN, FERİHA; CIRAKLI, Zeynep; ŞEKERLER, TURGUT; Izzettin, FİKRET VEHBİ; SANCAR, MESUT; OKUYAN, BETÜL; İZZETTİN, FIKRET VEHBI
    This study aims to determine the potential protective effects of ferulic acid against cisplatin-induced nephrotoxicity and to compare its effect with curcumin, a well-known protective agent against cisplatin- induced toxicity in rats. Administration of cisplatin resulted in high BUN (Blood Urea Nitrogen), creatinine, MDA (Malondialdehyde), MPO (Myeloperoxidase), TOS (Total Oxidative Status), PtNT (Protein Nitrotyrosine) levels (p < 0.05). Histological observations showed abnormal morphology of kidney; in addition with appearance of TUNEL positive cells indicating apoptosis in cisplatin administered group. HO-1 (Heme Oxygenase-1) levels measured by RT-PCR (Real Time Polymerase Chain Reaction), and TAS (Total Antioxidative Status) revealed antioxidant depletion due to cisplatin toxicity in animals (p < 0.05). All parameters showed improvement in groups treated with ferulic acid (p < 0.05). Ferulic acid treatment was found significant in preventing oxidative stress, increasing antioxidative status and regaining histological parameters to normal, indicating nephroprotective and antioxidant effects of this phenolic compound.
  • PublicationMetadata only
    The role of the clinical pharmacist in patient education and monıtoring of patients under warfarin treatment
    (2019-01-01) İZZETTİN, FİKRET VEHBİ; SANCAR, MESUT; AKSOY, NİLAY; TEZCAN, SONGÜL; BEKTAY, MUHAMMED YUNUS; İZZETTİN, FIKRET VEHBI; BEKTAY, MUHAMMED YUNUS
    This study was carried out on patients who were under anticoagulation treatment with warfarin, at the outpatient cardiology clinic. The aim was to determine the effectiveness of pharmacist consultation, education, and intervention on each patient-s therapeutic results. A cross-sectional randomized trial has been done. Twenty-five patients were included in the study. The Oral Anticoagulation Knowledge (OAK) Test, Short Form-36 (SF-36) and Duke Anticoagulation Satisfaction Scale (DASS) were applied. Patients resumed their routine anticoagulation treatment and INR and complications were recorded during the study. Additionally, patients received patient education, consultation on lifestyle and anticoagulant usage issues from a pharmacist. The same tests were applied again to the patients on the 90th day of the study and the results were compared with the initial test. Maintenance of INR within the target range and complication rates were compared before and after the intervention. Pre-test and post-test results of the patients revealed statistically significant improvements on the physical and mental score components of the SF-36 (p = 0.001; p = 0.001), OAK test scores (p <= 0.001) and the (negative) -limitations- and -burdens- and -positive effects- components of the DASS (p = 0.005; p < 0.001; p = 0.001). The successful maintenance of INR within target range was significantly higher (p = 0.027). The positive effects of pharmacist consultation and education on therapeutic results were demonstrated.
  • PublicationMetadata only
    Influence of Pharmacist Recommendations for Chemotherapy-Related Problems in Diabetic Cancer Patients
    (2017-01-01T00:00:00Z) Izzettin, Fikret V.; Al-taie, Anmar; SANCAR, MESUT; ALIUSTAOGLU, Mehmet; İZZETTİN, FIKRET VEHBI
    Drug related-problems pose additional worse outcomes in cancer patients treated with chemotherapy. A vital role of the clinical pharmacist is the detection and prevention of drug-related problems. The provision of patient education is an important step to reduce and prevent drug-related problems during chemotherapy administration. The objective of this study was to assess the occurrence of drug-related problems and the importance of effective provision of patient education and appropriate recommendations by the clinical pharmacist in reducing and solving of these problems in diabetic patients suffering from cancer.
  • PublicationMetadata only
    Importance of medication dose adjustment in hospitalized patients with impaired renal function at internal medicine ward: the possible impact of clinical pharmacist
    (2018-02-01T00:00:00Z) Altan, Aysenur; Ozkan, Oznur; DEMIRTUNC, Refik; OKUYAN, BETÜL; Izzettin, Fikret Vehbi; SANCAR, MESUT; İZZETTİN, FIKRET VEHBI
  • PublicationMetadata only
    Evaluation of drug burden index and medication utilization in geriatric patients at community pharmacy
    (2015-02-01T00:00:00Z) SANCAR, MESUT; Girgin, Irem; Selcuk, Aysu; Yang, Seonkyeong; Izzettin, Fikret Vehbi; OKUYAN, BETÜL; İZZETTİN, FIKRET VEHBI
  • PublicationMetadata only
    Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    (2018-06-01T00:00:00Z) Aypar, Eda; Izzettin, FİKRET VEHBİ; Aki, Sahika Zeynep; SANCAR, MESUT; Yegin, Zeynep Arzu; Turkoz-Sucak, Gulsan; İZZETTİN, FIKRET VEHBI
    Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.
  • PublicationMetadata only
    Validation of the Turkish version of medication regimen complexity index among elderly patients
    (2016-10-01T00:00:00Z) OKUYAN, BETÜL; Babi, Bedis; SANCAR, MESUT; Ay, Pinar; YUCEL, Emre; YUCEL, Aylin; Izzettin, Fikret Vehbi; İZZETTİN, FIKRET VEHBI
    ObjectiveThe aim of this study was to validate the Turkish version of the Medication Regimen Complexity Index- (MRCI).
  • PublicationMetadata only
    The assessment of self-medication utilization in pain management at a community pharmacy setting
    (2013-05-01T00:00:00Z) OKUYAN, BETÜL; Atalay, Mustafa Vakkas; Sahin, Ceren; Sahin, Duygucan; Izzettin, Fikret V.; SANCAR, MESUT; İZZETTİN, FIKRET VEHBI
  • PublicationMetadata only
    Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer
    (2018-03-01T00:00:00Z) TEZCAN, SONGÜL; Izzettin, Fikret Vehbi; SANCAR, MESUT; TURHAL, Nazim Serdar; YUMUK, PERRAN FULDEN; İZZETTİN, FIKRET VEHBI
    Objective To determine and evaluate the pharmaceutical care needs and quality of life of patients with colorectal cancer.